HUNG-YANG KUOJHE-CYUAN GUOCHIH-HUNG HSU2020-04-282020-04-2820200929-6646https://www.scopus.com/inward/record.uri?eid=2-s2.0-85074384022&doi=10.1016%2fj.jfma.2019.10.010&partnerID=40&md5=c0d706debb1a076a677166c44594a80dhttps://scholars.lib.ntu.edu.tw/handle/123456789/487248[SDGs]SDG2[SDGs]SDG3immunological antineoplastic agent; nivolumab; pembrolizumab; programmed death 1 receptor; programmed death 1 receptor antibody; unclassified drug; monoclonal antibody; PDCD1 protein, human; programmed death 1 receptor; advanced cancer; cancer immunotherapy; clinical practice; clinical trial (topic); esophageal squamous cell carcinoma; human; phase 3 clinical trial (topic); Short Survey; cell cycle checkpoint; drug effect; esophageal squamous cell carcinoma; esophagus tumor; immunotherapy; procedures; randomized controlled trial (topic); Antibodies, Monoclonal, Humanized; Cell Cycle Checkpoints; Clinical Trials, Phase III as Topic; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Immunotherapy; Programmed Cell Death 1 Receptor; Randomized Controlled Trials as Topicjournal article10.1016/j.jfma.2019.10.010316686502-s2.0-85074384022